Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Corey Cutler, Stephanie J. Lee, Sally Arai, Marcello Rotta, Behyar Zoghi, Aleksandr Lazaryan, Aravind Ramakrishnan, Zachariah DeFilipp, Amandeep Salhotra, Wanxing Chai-Ho, Rohtesh Mehta, Trent Wang, Mukta Arora, Iskra Pusic, Ayman Saad, Nirav N. Shah, Sunil Abhyankar, Carlos Bachier, John Galvin, Annie ImAmelia Langston, Jane Liesveld, Mark Juckett, Aaron Logan, Levanto Schachter, Asif Alavi, Dianna Howard, Harlan W. Waksal, John Ryan, David Eiznhamer, Sanjay K. Aggarwal, Jonathan Ieyoub, Olivier Schueller, Laurie Green, Zhongming Yang, Heidi Krenz, Madan Jagasia, Bruce R. Blazar, Steven Pavletic

Research output: Contribution to journalArticlepeer-review

116 Scopus citations

Fingerprint

Dive into the research topics of 'Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds